



Invitation to presentation of Acarix´s third quarter 2024 report

Acarix invites investors, analysts, and media to a webcast presentation of the third quarter report for 2024 on November 7, 15:00 CET. The report will be published during the morning of the same day.

The presentation will be held by CEO Aamir Mahmood and CFO Christian Lindholm. After the presentation, there will be a Q&A session moderated by Ludvig Svensson, analyst at Carnegie Investment Bank. The presentation will be held in English.

Date and time: Thursday, November 7, 15:00 CET

Questions to moderator can be sent by email in advance to Ludvig.svensson@carnegie.se before 17:00 CET on Nov 6.

The presentation will also be accessible at Acarix website

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact

Ashley Wilson, phone +1405 413 5201, email awilson@saxum.com

Attachments

[Invitation to presentation of Acarix´s third quarter 2024 report](#)